A single-center, double-blind, randomized, placebo-controlled Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-1014-6470 in healthy subjects, including food effect, mass balance, and metabolite profiling

Published: 14-10-2019
Last updated: 17-01-2025

Main objectivesTo evaluate the safety and tolerability of single- and multiple-ascending dose (SAD and MAD) administration of ACT-1014-6470 in healthy subjects.To investigate the pharmacokinetics (PK) of SAD and MAD administration of ACT-1014-6470...

Ethical review	Approved WMO
Status	Completed
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON48421

Source
ToetsingOnline

Brief title
SAD, MAD, ADME of ACT-1014-6470 in healthy subjects

Condition

- Other condition

Synonym
inflammatory diseases

Health condition

inflammatory diseases

Research involving
Human

Sponsors and support

Primary sponsor: Idorsia Pharmaceuticals Ltd
Source(s) of monetary or material Support: Pharmaceutical Industry

Intervention

Keyword: ACT-1014-6470, ADME, Healthy volunteers, SAD/MAD

Outcome measures

Primary outcome

PART A (SAD)

All cohorts under fed conditions

- Area under the plasma concentration-time curve (AUC) from zero to infinity

(AUC0-inf)

Secondary outcome

All cohorts under fed conditions

- Maximum plasma concentration (Cmax).

- Time to reach Cmax (tmax).

- t*.

Food effect evaluation only

- AUC0-inf under fasted conditions.

- Cmax under fasted conditions.

- tmax under fasted conditions.

- t* under fasted conditions.

PART B (MAD)

- AUC during a dosing interval (AUCtau) following the first and the last dose.

Safety

- Treatment-emergent adverse events (AEs) from the start of the study treatment

administration up to End-of-Study (EOS) or End-of-Period (EOP).

- Treatment-emergent serious AEs from the start of the study treatment

administration up to EOS or EOP.

Study description

Background summary

ACT-1014-6470 has not been administered to humans before. It has been previously tested in the laboratory and on animals.

Study objective

Main objectives
To evaluate the safety and tolerability of single- and multiple-ascending dose (SAD and MAD) administration of ACT-1014-6470 in healthy subjects.

To investigate the pharmacokinetics (PK) of SAD and MAD administration of ACT-1014-6470 in healthy subjects.

Other objectives
To investigate the effect of food on the PK of ACT-1014-6470 after single-dose administration in healthy male subjects.

To investigate the absorption, distribution, metabolism, and excretion (ADME) characteristics of ACT-1014-6470 after a single oral administration of a

14C-radiolabeled ACT-1014-6470 microtracer in healthy male subjects.

Study design

Part A:
Cohorts A1, A2, A4, A5, A6: single dose
Cohort A3: 2 doses separated by at least 18 days

Part B: The treatment duration will not exceed 2 weeks.

Intervention

ACT-1014-6470 or placebo will be given once (multiple administrations in part B) in the morning as oral capsule(s). In Group A4, ACT-1014-6470 (or placebo) and 14C-ACT-1014-6470 (or placebo) will be given at the same time.

Study burden and risks

As ACT-1014-6470 will be administered to humans for the first time in this study, side effects of ACT-1014-6470 in humans have not been reported to date. However, ACT-1014-6470 has been studied extensively in the laboratory and in animals.

Contacts

Public
Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91
Allschwil 4123
CH
Scientific
Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91
Allschwil 4123
CH

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

General criteria
- Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
- Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years (inclusive) at Screening.
- Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
- Male subjects with a partner who might become pregnant must either be vasectomized or agree to practice adequate contraception from admission to the study site until 3 months after dosing, or the partner must consistently and correctly use a highly effective method of contraception.

Criteria for Part B
- Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a highly effective method of contraception with a failure rate of < 1% per year, be sexually inactive, or have a vasectomized partner.
- Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

Exclusion criteria

General criteria
- Pregnant or lactating women.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).

Criteria for the ADME evaluation (Part A) only
- Radiation exposure, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant Ionising Radiation Regulations, must not participate in the study.
- Participation in any study involving administration of any 14C-radiolabeled compound within the 12 months prior to Screening.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Completed
Start date (anticipated):	06-11-2019
Enrollment:	88
Type:	Actual

Ethics review

Approved WMO Date:	14-10-2019
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	13-11-2019
Application type:	First submission

Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	21-04-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2019-003347-30-NL
CCMO	NL71553.056.19

Study results

Date completed:	17-07-2020
Results posted:	15-02-2021

First publication
08-01-2021